RxDoctor Payments Data

Michael Yunes

Radiation Oncology · Springfield, MANPI 1942391891

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,775 of the $19,808 with a category attached, or 64.5%. Elekta, Inc. accounts for 98.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $11,243 and has fallen 97.0% since, to $343 in 2025. Among radiation oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,808in general payments, 2019–2025

Across 41 payments — averaging $483.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Elekta, Inc.$20K
  • Novocure Inc.$162
  • Siemens Medical Solutions USA, Inc.$56
  • Bioprotect Medical, Inc.$33
  • Boston Scientific$29
  • Teleflex LLC$14

What the payments were for

  • Consulting fees$12,77564%
  • Travel & lodging$5,28127%
  • Food & beverage$1,7329%
  • Entertainment$210%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,808 in reported general payments places this provider in the 90th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$153,962
Medicare patients
151
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl13$252
Dexamethasone16$212

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →